[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

NRIX : 23.48 (+3.39%)
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration...

NRIX : 23.48 (+3.39%)
Nurix Therapeutics Reports This Week With Its Cash Runway Now a More Urgent Question

Barchart Research What to Expect from NRIX Earnings NRIX Generated July 7, 2026 Current Price $24.40 EPS Estimate $$-0.73 Consensus Rating Strong Buy Average Move 6.53% Nurix Therapeutics Reports This...

NRIX : 23.48 (+3.39%)
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median...

NRIX : 23.48 (+3.39%)
Broader Market Settles Higher as Chipmakers Rally

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.30%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.58%. June E-mini...

MSTR : 101.95 (+4.22%)
MPC : 319.76 (+1.41%)
AAPL : 327.74 (+0.35%)
SNDK : 1,589.40 (+14.27%)
GLXY : 25.41 (+7.40%)
SLB : 46.59 (+0.43%)
COIN : 175.85 (+9.61%)
CIEN : 408.73 (+7.91%)
FANG : 199.80 (+2.26%)
STX : 891.83 (+11.14%)
WDC : 548.39 (+12.51%)
AMD : 544.43 (+8.11%)
Stocks Rally as Buyers Return After AI-Led Selloff

The S&P 500 Index ($SPX ) (SPY ) today is up +1.01%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.39%. June E-mini S&P futures (ESM26...

MSTR : 101.95 (+4.22%)
MPC : 319.76 (+1.41%)
SNDK : 1,589.40 (+14.27%)
ADI : 382.81 (+2.78%)
GLXY : 25.41 (+7.40%)
SLB : 46.59 (+0.43%)
COIN : 175.85 (+9.61%)
CIEN : 408.73 (+7.91%)
FANG : 199.80 (+2.26%)
STX : 891.83 (+11.14%)
WDC : 548.39 (+12.51%)
AMD : 544.43 (+8.11%)
Stocks Push Higher as Chipmakers and AI Companies Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.59%. June E-mini S&P futures (ESM26...

MSTR : 101.95 (+4.22%)
AMAT : 564.55 (+7.39%)
AVGO : 386.50 (+2.21%)
SNDK : 1,589.40 (+14.27%)
ADI : 382.81 (+2.78%)
GLXY : 25.41 (+7.40%)
WIX : 51.12 (-4.20%)
$IUXX : 29,155.18 (+1.93%)
COIN : 175.85 (+9.61%)
ZNU26 : 108-205 (-0.20%)
CIEN : 408.73 (+7.91%)
ESU26 : 7,541.00 (+0.76%)
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust...

NRIX : 23.48 (+3.39%)
RHHBY : 51.1400 (+0.27%)
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers,...

NRIX : 23.48 (+3.39%)
Nurix Therapeutics to Participate in Upcoming Investor Conferences

BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted...

NRIX : 23.48 (+3.39%)

Barchart Exclusives

The UFO ETF Is Crashing Back to Earth as SpaceX Stock Treads Water Below $135
There’s no denying that the space industry has plenty of long-term potential. But as I’ve seen for a decade, pulling future returns forward is a recipe for disaster. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.